Y90 Radioembolization for Locally Advanced HCC

UCLA Health

S. Padia

HCC Percutaneous Radio-Ablation Using BAT-90: Results of an Ongoing …

Malkhaz Mizandari

SIR 2024 Insights: Route90 US IDE Pivotal Study Early Results in Rad…

SIR 2024 Insights

A. Kennedy

Colorectal Liver Metastases: Liver-Directed Therapies - Embolization…

Penn Medicine Abramson Cancer Center

M. Soulen

New and Evolving Clinical Trials: Embolotherapy

SIR 2022 Coverage

M. Soulen

Dosing Radioembolization for HCC: Why Dose Calculation Is the Most I…

Shamar Young

LEGACY: A Multicenter Study Confirming TheraSphere™ as a Neoadjuvant…

Boston Scientific

V. Bishay

Liver Directed Therapy in 2021: What Are the Advances in Transarteri…

UCLA Health

S. Padia

TheraSphere™ Y-90 Glass Microspheres: The DOSISPHERE-01 Trial

Boston Scientific

Liver-Directed Therapy for mCRC: What Is the Goal, When to Use and H…

Memorial Sloan Kettering Cancer Center

A. Cercek

Stage C HCC Clinical Data Review: Resin Radioembolization and Kinase…

Cedars Sinai

J. Marrero, W. C. Maddrey

TheraSphere™ Y-90 Glass Microspheres: The LEGACY Study

Boston Scientific

2L Yttrium-90 Radioembolization With Chemo for CRC Liver Metastases

ecancer

M. Mulcahy

Y90 Radiation Segmentectomy

Siddharth Padia

Embolization Optimization with Proximal Protection: Principles and P…

Theresa Caridi

Practical Approach to Y90 Dosimetry: Using the DAVYR App

Ripal Gandhi

Principles of Y90 Dosimetry

Ripal Gandhi

Liver Case Review: 9.5 cm Liver Mass- HCC

Symposium on Clinical Interventional Oncology (CIO 2018)

Macroaggregated Albumin (MAA) Prior to Planned SIRT Y90 Segmentectomy

TREAT Symposium

E. Kim

MAA Mapping for SIRTEX Y90 Lobectomy: High CFA Access Risk

TREAT Symposium

A. Fischman